Navigation Links
Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
Date:4/2/2008

-Milestone triggers $28.3 million second-tranche investment-

CAMBRIDGE, Mass., April 2, 2008 /PRNewswire/ -- Radius Health ("Radius") announced today the completion of patient enrollment into its Phase II clinical trial of BA058, the company's bone anabolic candidate for treatment of osteoporosis. The Phase II dose-finding study is designed to further evaluate the ability of BA058 to build new bone for the treatment of osteoporosis in postmenopausal women. Radius also announced today the receipt of a second-tranche financing of $28.3 million based on achieving this milestone, for a total second institutional investment of $67.5 million. Six existing venture investors-MPM Capital, The Wellcome Trust, HealthCare Ventures, Oxford Bioscience Partners, BB Biotech Ventures, and Scottish Widows Investment Partnership-participated in the latest closing. Radius will use the funds to support development of the company's four major product candidates.

The randomized, double-blind, placebo- and comparator-controlled Phase II study is evaluating BA058 in 244 otherwise healthy postmenopausal women with osteoporosis at 35 centers in the United States, United Kingdom, Argentina, and India. The trial is designed to evaluate the safety of BA058 across a range of doses as well as its ability to induce bone formation without inducing resorption through measurement of bone formation and resorption markers and by measuring bone mineral density using a number of different modalities. Radius expects to report the results of the Phase II clinical trial by the end of 2008.

"The completion of patient recruitment in this Phase II trial is a very significant achievement for Radius, and we are grateful for the enthusiasm of our investigators, who have worked diligently to exceed our enrollment target for this study," said C. Richard Lyttle, PhD, President and CEO of Radius. "We believe that BA058 represents a next-generation bone anabolic treatment for osteoporosis that promises to build bone more rapidly and to be more convenient for patients to use. We look forward to communicating the results later this year."

About BA058

PTHrP (parathyroid hormone-related protein) is a critical peptide for promoting new bone formation, with a role distinct from PTH (parathyroid hormone), which regulates calcium homeostasis and bone resorption. BA058 is an analog of hPTHrP that is designed to build bone without inducing hypercalcemia or significant resorption. In preclinical testing, BA058 demonstrated the potential to widen the anabolic window for bone therapeutics: i.e., stimulating bone formation with a limited effect on bone resorption. In Phase I studies, BA058 generally was well tolerated and did not induce hypercalcemia in doses up to 80 mcg.

About Osteoporosis

Osteoporosis is a leading cause of morbidity and mortality in elderly people worldwide. In the U.S. alone, more than 44 million men and women have osteoporosis or low bone-mineral density. A 50-year-old woman in the U.S. has a 40 percent lifetime risk of osteoporotic fracture. Twenty percent of hip- fracture patients enter long-term care, and half of this group never returns to living independently.

About Radius (http://www.radiuspharm.com)

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. Radius has raised $91.5 million in private equity financing since its establishment in 2003 and is based in Cambridge, Massachusetts.

Contact:

Nick Harvey

Chief Financial Officer

(617) 551-4704


'/>"/>
SOURCE Radius
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
3. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
4. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
5. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
6. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
7. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
10. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
11. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in developing countries are ... BCC Research reveals in its new report that markets in ... see strong growth due to rising government healthcare spending, increased levels of ... Continue Reading ... ...
(Date:1/23/2017)... Spain , January 23, 2017 /PRNewswire/ ... biopharmaceutical company focused on treatments for calcification disorders, ... enrolled in the Phase IIb "CaLIPSO Study" clinical ... of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients ... in the last stage of chronic kidney disease, ...
(Date:1/22/2017)... , Saudi Arabia , January 22, 2017 ... US and UAE discuss ... at the World Economic Forum   "The management and ... big data and powered by artificial intelligence and this trend is going to ... ,Hospital of the Future, at the concluding day of the 47 th ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... The January 2017 issue of the Journal ... on how outdoor behavioral healthcare (OBH) – also known as wilderness therapy – helped ... experiencing an increased sense of purpose both during and after treatment. , The ...
(Date:1/24/2017)... Ariz. (PRWEB) , ... January 23, 2017 , ... ... recently analyzed statistics from 140 Buzzies users who entered metrics into the product’s ... earlier clinical data. The new data showed that within just 30 seconds of ...
(Date:1/24/2017)... Clara, CA (PRWEB) , ... January 23, 2017 ... ... announces the launch of a new plugin that allows sleep centers to automatically ... Sleep Device Interface (SDI)—is a thin client browser plugin is quickly installed on ...
(Date:1/23/2017)... ... January 23, 2017 , ... A Northwestern Pennsylvania addiction ... address. Alpine Springs Rehabilitation & Recovery Center’s new website can be found at ... with its redesigned and retooled website. The treatment center has also revamped its ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... for life science companies, has achieved ISO 17100:2015 certification following a comprehensive ... 17100 is the globally recognized standard that establishes guidance for critical processes ...
Breaking Medicine News(10 mins):